A Story Worth Telling: The Evolution of Haemophilia Care in Canada

Understanding the historical development of haemophilia care is essential to informed contemporary clinical practice in bleeding disorders. Hopelessness to Normalcy: The Remarkable History of Hemophilia Care in Canada [1] by Drs. Man-Chiu Poon and Robert Card draws on extensive interviews to trace the evolution of care with clarity and nuance, offering a relevant and informative account for clinicians at all stages of their careers. Though unfamiliar to many—particularly those early in their training—this rich history offers critical context that can deepen the quality of care provided to individuals with haemophilia. Haemophilia, historically referred to as the “Royal disease,” gained early public recognition through its prevalence in European royal bloodlines, particularly amongst Queen Victoria's descendants [2, 3]. Awareness of this history heightened societal interest and helped shape early scientific inquiry and perceptions of the disease. As the authors note, “The case of Prince Leopold illustrates the grim prognosis of haemophilia without effective treatment. His mother, Queen Victoria, had access to the best physicians…but none were able to help” (5) [1]. The themes of adaptability, advocacy, mentorship, ethical responsibility, and historical awareness that emerge from Poon and Card's narrative provide a meaningful lens through which to examine contemporary haemophilia care. Poon and Card effectively illustrate the therapeutic evolution in haemophilia care from the disappointment of whole blood transfusions to the early successes of plasma fractionation that led to the development of sophisticated, patient-centred therapies. Their narrative captures the profound impact of cryoprecipitate in the 1960s—a turning point that enabled more efficient dosing and made home treatment possible, though not without significant challenges. One patient reflects, “Cryo was often a two-person job—sticky, difficult to infuse. Needed biggest buddy from high school to squeeze the glass syringes” (45) [1], while another recalls the logistical barriers to travel: “When we travelled from London to Saskatoon, we kept cryo in the car and called ahead to have dry ice available at daily stops along the way” (46) [1]. These patient narratives illuminate the experiences of early therapeutics and underscore the scale of transformation introduced by lyophilized concentrates, and later, by recombinant and extended half-life products. Poon and Card frame these developments within a broader shift toward autonomy and normalization in the lives of people with haemophilia—offering clinicians a deeper appreciation of how current standards of care are historically grounded. A key strength of Hopelessness to Normalcy lies in its detailed account of how advances in haemophilia therapeutics were paralleled by the development of systems that enabled their effective delivery. Poon and Card highlight that the impact of innovations such as cryoprecipitate and factor concentrates was magnified by the emergence of comprehensive care programs—most notably at Montreal's St. Mary's Hospital Center and the Montreal Children's Hospital—which pioneered coordinated, multidisciplinary approaches to patient management. These Canadian programs were part of a broader international movement, with early comprehensive care initiatives emerging in several high-resource countries, reflecting a global recognition of the need for multidisciplinary, patient-centred models of haemophilia care [3]. Equally transformative, in the Canadian setting, was the founding of the Canadian Hemophilia Society (CHS) in 1953. The authors underscore the CHS's role in shaping policy, advocating for access to treatment, and promoting patient safety. Through sustained collaboration with clinicians, policymakers, and researchers, the CHS helped advance treatment standards and ensured that therapeutic innovations translated into meaningful improvements in care. The partnership between organized patient groups and the clinical community, as portrayed throughout the book, emerges as a foundational pillar in the evolution of haemophilia care in Canada. Today, the CHS continues to play a vital role as a national patient organization—supporting research, advocating for equitable access to emerging therapies and ensuring that the voices of individuals with bleeding disorders remain central to care and policy decisions. The book offers an honest and sobering account of the optimism that accompanied major therapeutic advances, sharply disrupted by the unforeseen tragedy of the HIV/AIDS crisis in the 1980s. Poon and Card capture this turning point with a moving reflection: “Hemophilia appeared to have entered its golden period at last. Little did they know how rapidly things could change” (63) [1]. The devastating consequences of contaminated blood products are conveyed with honesty. As they write, “The regret and sorrow that the same treatment once hoped to improve patients’ lives had caused so many unnecessary deaths was still raw and painful many years later. Losing young patients and children was particularly dreadful” (83) [1]. The authors emphasize the scale of loss and its enduring toll on the community: “The HIV crisis led to the premature death of a generation of haemophilia patients and reversed the gains in life expectancy…” (78) [1]. This period stands as a stark reminder of the moral responsibility borne by clinicians and health systems—and of the enduring imperative for vigilance, transparency, and patient-centred safeguards in care delivery. Out of the depths of the HIV/AIDS crisis emerged a profound resilience and a renewed commitment to collaboration and advocacy. Poon and Card highlight this recovery period, observing: “Yet both groups [patients and healthcare professionals] were resilient. They worked together, advocated for each other, learned from those experiences, and forged forward to a much better future” (139) [1]. An additional healthcare professional was quoted: “…as tough as the times were, during this period hardly any of the HCPs [healthcare providers] quit and said ‘I cannot handle this…’ They stuck with it and carried on. No one deserted.” [1] The spirit of partnership forged through adversity remains a cornerstone of haemophilia care today. The establishment of the Association of Hemophilia Clinic Directors of Canada (AHCDC) in 1994 was a key milestone in formalizing this collaboration—advancing national standards for comprehensive care, implementing surveillance frameworks, and developing robust patient-management systems. In parallel, the Krever Inquiry, catalysed by the tainted blood scandal, prompted a sweeping transformation in Canadian haemophilia care [4]. Its recommendations mandated rigorous standards for blood product safety and institutional oversight, fundamentally reshaping clinical governance and restoring public trust. While Hopelessness to Normalcy chronicles the evolution of haemophilia care in Canada—a high-resource setting—it also serves as a powerful reminder that many of the historical challenges detailed by Poon and Card persist globally. Poon and Card's advice to “Be vigilant! Avoid complacency! Be prepared to adapt!” (116) [1] serves as a timely reminder of the necessity for sustained vigilance, ethical reflection, and adaptability in clinical practice, principles crucial to the global healthcare landscape. As the haemophilia therapeutic landscape continues to evolve quickly—with innovations such as gene therapy, rebalancing therapies and factor-mimetics—the historical insights offered in this book remain profoundly relevant. As haematologists caring for haemophilia patients today and entering an era where the bar for effective haemophilia therapies is set at zero bleeds, with the allure of a “hemophilia-free mind” [5] and a broader range of therapeutic options, it is easy to forget the challenges and important successes of our predecessors. Hopelessness to Normalcy is “part history and part memoir,” as Poon and Card put it at a recent Canadian Society of History of Medicine reception. It behoves us haematologists who did not live through the excitement of discovering cryoprecipitate and the heartbreak of the HIV/AIDs crisis, to gain insight into this through Poon and Card's reflections. We too carry a responsibility to preserve and pass on these lived-experiences and lessons of collaboration to the next generation of haemophilia clinicians. As in one of Marcus Garvey's powerful quotes: “A people without the knowledge of their past history and origin, is like a tree without roots,” Hopelessness to Normalcy is an essential and foundational resource for clinicians involved in the care of persons with haemophilia. It not only deepens our understanding of the disease but reminds us of the power of patient society–medical association partnerships and how much is achieved through collaboration toward a common goal—making lasting improvements in haemophilia care. It serves as both a tribute to the journey we have made and a call to action, urging us to continue advancing care with the same spirit of unity and dedication that has shaped the past. K.U. prepared the first draft of the manuscript. A.L. contributed to the manuscript through critical input and both substantive and editorial revisions. Both the authors read and approved the final version. This manuscript is a commentary and does not involve any original research involving human participants or animals. As such, ethics approval and informed consent were not required. KU has received educational grants from CSL Behring, Roche, and Novo Nordisk, research funding from Bayer and Novo Nordisk, consultancy fees from Bayer, Biocryst Pharmaceuticals, Novo Nordisk, Roche, Sanofi, and Takeda, speaker fees from Bayer, CSL Behring, Pfizer, Roche, Sanofi, and Takeda, and travel support from Novo Nordisk, Octapharma, Roche, and Sanofi. AL has received consultancy fees from Sanofi, Roche, Sobi, and Leo Pharma; speaker fees from Pfizer, Takeda, and Novo Nordisk. No new data were generated or analysed in support of this research.